Morgan Stanley Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $20
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $20.
Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $20.